Decades-Old Transplant Drug Shows Promise in Delaying Type 1 Diabetes Progression
A new study suggests that a decades-old transplant drug, polyclonal antithymocyte globulin (ATG), can delay the progression of type 1 diabetes in newly diagnosed patients. The study found that a lower dose of ATG is nearly as effective as higher doses in preserving insulin-producing beta cells, with fewer side effects. The trial included 117 participants aged 5 to 25, showing that the lowest dose preserved beta cell function for a year. This approach targets the 'honeymoon phase' soon after diagnosis, where beta cells still produce some insulin, potentially reducing diabetes complications. 
